As CEO and Majority Shareholder of Industria Quimico Farmaceutica Sigma Corp. (Sigma Corp.), Patricia has played a pivotal role in transforming Bolivia's pharmaceutical landscape, overseeing regulatory advancements, and spearheading international trade initiatives. Under her leadership, Sigma Corp. expanded its manufacturing capabilities, establishing state-of-the-art pharmaceutical infrastructure compliant with European export standards, and positioning the company to be a regional powerhouse in API production, research, and global distribution.
With this appointment, Patricia will be responsible for KRTL's global pharmaceutical sales strategy, leading market penetration efforts, developing key strategic alliances, and ensuring KRTL's compliance-driven expansion in regulated pharmaceutical and biopharmaceutical markets. She will collaborate closely with KRTL Biotech and KRTL International to integrate global trade, regulatory expertise, and pharmaceutical supply chain efficiency into KRTL's commercial strategy.
"Marlen Patricia Wilstermann-Sanzetenea's appointment is a milestone for KRTL's global expansion," said Cesar Herrera, CEO of KRTL Holding Group Inc. "Her deep industry knowledge, regulatory expertise, and ability to navigate complex international markets make her an invaluable addition to our leadership team. With her guidance, KRTL will strengthen its position in pharmaceutical innovation and global distribution."
Patricia's leadership will be instrumental in scaling KRTL's pharmaceutical sales division, leveraging her experience in strategic business development, international compliance, and API commercialization. Her proven track record of market growth, regulatory structuring, and pharmaceutical innovation aligns with KRTL's commitment to scientific excellence, regulatory transparency, and sustainable business expansion.
About KRTL Holding Group Inc.
KRTL Holding Group Inc. is a dynamic holding company operating through its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. These subsidiaries specialize in biopharmaceutical innovation, international trade, and compliance-driven healthcare advancements. By leveraging strategic mergers, acquisitions, and joint ventures, KRTL Holding Group continues to push the boundaries of scientific research, regulatory compliance, and global business solutions.
Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
This press release contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, anticipated business developments, regulatory advancements, and strategic growth plans. Such forward-looking statements involve known and unknown risks that may cause actual results to differ materially from those expressed or implied.
KRTL Holding Group assumes no obligation to update or revise forward-looking statements, except as required by law. Any updates will be made in accordance with applicable SEC regulations and disclosure obligations. Readers are cautioned not to place undue reliance on forward-looking statements.
Comments